Uterine Mesonephric-like Adenocarcinoma: Correlations between Mismatch Repair Protein Expression and Microsatellite Instability and Responses to Lenvatinib Plus Pembrolizumab Combination Therapy

被引：0
|
作者：
Kim, Hyunjin [1 ]
Kim, Hyun-Soo [2 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
LABORATORY INVESTIGATION | 2022年 / 102卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
721
引用
收藏
页码：777 / 777
页数：1
相关论文
共 7 条
  • [1] Uterine Mesonephric-like Adenocarcinoma: Correlations between Mismatch Repair Protein Expression and Microsatellite Instability and Responses to Lenvatinib Plus Pembrolizumab Combination Therapy
    Kim, Hyunjin
    Kim, Hyun-Soo
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 777 - 777
  • [2] Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comparison Between Mismatch Repair Protein Immunostaining and Microsatellite Instability Testing
    Kim, Hyunjin
    Kim, Hyun-Soo
    ANTICANCER RESEARCH, 2023, 43 (04) : 1785 - 1795
  • [3] Mesonephric-like adenocarcinoma of the uterine corpus: comparison of GATA-binding protein 3 Expression and its diagnostic performance among different antibody clones
    Kim, H.
    Kim, H.
    VIRCHOWS ARCHIV, 2024, 485 : S89 - S89
  • [4] Concordance between microsatellite instability and mismatch repair protein expression in colorectal cancer and their clinicopathological characteristics: a retrospective analysis of 502 cases
    Ye, Meihua
    Ru, Guoqing
    Yuan, Hang
    Qian, Lili
    He, Xianglei
    Li, Shuangshuang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer
    Andre, T.
    Sposetti, C.
    Gumus, M.
    Ahn, J. Bae
    Wyrwicz, L.
    Kwiatkowski, M.
    Kim, J.
    Yalcin, S.
    Sendur, M.
    Odeleye-Ajakaye, A.
    Leconte, P.
    Fogelman, D.
    Kim, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S256 - S257
  • [6] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
1